Microbial Fermentation Technology Market Size

  • Report ID: 5329
  • Published Date: Oct 09, 2024
  • Report Format: PDF, PPT

Microbial Fermentation Technology Market Size

Microbial Fermentation Technology Market size was valued at USD 34.92 billion in 2024 and is set to reach USD 73.57 billion by the end of 2037, registering around 5.9% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of microbial fermentation technology is assessed at USD 36.57 billion. The reason behind the growth is due to the rising need for vaccines. Microbial fermentation is a potent, adaptable microbiology method used to generate microbial cells or biomass such as proteins and enzymes for vaccine synthesis, and is also considered crucial in the production of mRNA vaccines. Moreover, it is the most prevalent process of vaccine manufacture followed by purification, which takes about 3 weeks. According to the World Health Organization (WHO), in 2021, over 16 billion vaccination shots costing USD 141 billion were distributed across the globe.

The growing need for microbial contract manufacturing services is believed to fuel the market growth. It has led to the development of a wide range of microbial products, microbial biomass, and enzymes, and has enabled many sorts of bulk manufacturing based on microbial fermentation.  Besides this, it has led to advancements in bioprocessing which would make the fermentation process more efficient and reliable in the coming years.


Microbial Fermentation Technology Market Overview
Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 5329
  • Published Date: Oct 09, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of microbial fermentation technology is assessed at USD 36.57 billion.

The microbial fermentation technology market size was valued at USD 34.92 billion in 2024 and is set to reach USD 73.57 billion by the end of 2037, registering around 5.9% CAGR during the forecast period i.e., between 2025-2037. The rising need for vaccines and the growing need for microbial contract manufacturing services will drive the market growth.

Asia Pacific industry is set to dominate majority revenue share 42% by 2037, impelled by presence of the developed chemical sector in the region.

The major players in the market are BioVectra Inc., Danone UK, F. Hoffmann-La Roche AG, Koninklijke DSM NV, Lonza, Novozymes A/S, TerraVia Holdings, Inc., BIOZEEN
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample